世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の放射免疫療法産業調査レポート、成長動向と競争分析 2023-2029


Global Radioimmunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2023-2029

COVID-19のパンデミックにより、世界の放射免疫療法の市場規模は2022年に1億4283万米ドルであり、2023年から2029年の予測期間中のCAGRは17.43%で、2029年までに4億4779万米ドルに再調整されると予測されている。... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2023年7月28日 US$5,600
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

COVID-19のパンデミックにより、世界の放射免疫療法の市場規模は2022年に1億4283万米ドルであり、2023年から2029年の予測期間中のCAGRは17.43%で、2029年までに4億4779万米ドルに再調整されると予測されている。

ラジオ免疫療法の世界の主要企業には、バイエル、ノバルティス、ランテウス、オーロビンド・ファーマ、ムンディファーマ、中国アイソトープ・放射線、キュリウム・ファーマシューティカルズなどが含まれる。2022年には、世界の上位5社が売上高で約99.25%のシェアを占めている。
米国のラジオ免疫療法市場規模は2022年に5億462万米ドルであり、中国規模は2372万米ドルであった。米国の割合は2022年に48.39%であったが、中国の割合は2.27%であり、中国のシェアは2029年に1.44%に達し、分析期間を通じて20.26%のCAGRをたどると予測されている。欧州の放射線免疫療法に関しては、ドイツは2029年までに3億2700万米ドルに達すると予測されている。

この調査レポートは、メーカー、利害関係者、意思決定者、その他の市場参加者が、世界の放射線免疫療法市場の成長に影響を与えるあらゆる要因に精通するのに役立つ非常に有用な資料です。本レポートを執筆したアナリストは、世界のRadioimmunotherapy市場のトップ企業が採用する主要戦略を綿密に調査しました。また、SWOTなどの市場分析も行い、世界のRadioimmunotherapy市場の重要な側面について明確かつ深い理解を提供します。本レポートの読者は、世界のRadioimmunotherapy市場の現在および将来の動向と、それらが予測期間中の市場成長にどのような影響を与えるかについて知ることができます。

企業別
バイエル
ノバルティス
ランテウス
オーロビンド・ファーマ
ムンディファーマ
中国アイソトープ・放射線
キュリウム・ファーマシューティカルズ
パイプライン
ギリアド・サイエンシズ
クラリティ・ファーマシューティカルズ
キュラサイト
ノルディック・ナノベクター
フィロゲン
ラジオメディックス
テリックス・ファーマシューティカルズ
オラノメッド
アクティニウム・ファーマシューティカルズ
Y-mAbsセラピューティクス
フュージョン・ファーマシューティカルズ

タイプ別セグメント
ベータ線放出
標的α療法

用途別セグメント
非ホジキンリンパ腫(NHL)
固形がん

地域別
北米
米国
カナダ

アジア太平洋
中国
日本
韓国
インド
東南アジア

ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア

ラテンアメリカ
メキシコ
ブラジル

中東・アフリカ
中東
アフリカ

各章の概要
第1章:報告書のスコープ、異なる市場セグメント(製品タイプ、アプリケーションなど)のエグゼクティブサマリー、各市場セグメントの市場規模、将来の発展の可能性などを紹介します。
第2章:世界および地域レベルでの放射線免疫療法の収益。
第3章:ラジオ免疫療法企業鈥の競争環境、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。
第4章:各種市場セグメントをタイプ別に分析し、各市場セグメントの収益、発展の可能性を網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけるのに役立つ。
第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、発展の可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第6章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の収益。
第7章:ヨーロッパ:タイプ別、用途別、国別、セグメント別収益
第8章:アジア太平洋地域:タイプ別、用途別、地域別、セグメント別収益
第9章:ラテンアメリカ:タイプ別、用途別、国別、セグメント別収益。
第10章: 中東・アフリカ: タイプ別、用途別、国別、セグメント別収益。
第11章:主要企業のプロファイルを提供し、製品の説明や仕様、ラジオイムノセラピーの収益、売上総利益率、事業戦略など、市場の主要企業の基本的な状況を詳細に紹介します。
第12章:市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を紹介します。
第13章 調査結果と結論

ページTOPに戻る


目次

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1
1.2.2 Targeted Alpha Therapy 3
1.2.3 Beta-emitting 4
1.3 Market by Application 7
1.3.1 Global Radioimmunotherapy Market Growth by Application: 2018 VS 2022 VS 2029 7
1.3.2 Non Hodgkin Lymphoma (NHL) 9
1.3.3 Solid Tumor 10
1.4 Assumptions and Limitations 12
1.5 Study Objectives 13
1.6 Years Considered 14
2 Market Perspective 15
2.1 Global Radioimmunotherapy Market Size 2018-2029 15
2.2 Radioimmunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029 16
2.3 Global Radioimmunotherapy Market Size by Region (2018-2023) 18
2.4 Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) 20
2.5 Global Top 10 Radioimmunotherapy Countries Ranking by Market Size 21
3 Radioimmunotherapy Competition by Company 23
3.1 Global Radioimmunotherapy Revenue by Players 23
3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2023) 23
3.1.2 Global Radioimmunotherapy Market Share by Players (2018-2023) 24
3.2 Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) 25
3.3 Company Covered: Ranking by Radioimmunotherapy Revenue 25
3.4 Global Radioimmunotherapy Market Concentration Ratio 26
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI) 26
3.4.2 Global Top 5 Companies by Radioimmunotherapy Revenue in 2022 27
3.5 Global Key Players of Radioimmunotherapy Head office and Area Served 27
3.6 Global Key Players of Radioimmunotherapy, Product and Application 28
3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28
3.8 Mergers & Acquisitions, Expansion Plans 29
4 Global Radioimmunotherapy Breakdown Data by Type 30
4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2023) 30
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) 31
5 Global Radioimmunotherapy Breakdown Data by Application 32
5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2023) 32
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) 33
6 North America 34
6.1 North America Radioimmunotherapy Revenue by Company (2021-2023) 34
6.2 North America Radioimmunotherapy Revenue by Type (2018-2029) 35
6.3 North America Radioimmunotherapy Revenue by Application (2018-2029) 36
6.4 North America Radioimmunotherapy Revenue by Country (2018-2029) 37
6.4.1 United States 38
6.4.2 Canada 39
7 Europe 40
7.1 Europe Radioimmunotherapy Revenue by Company (2021-2023) 40
7.2 Europe Radioimmunotherapy Revenue by Type (2018-2029) 41
7.3 Europe Radioimmunotherapy Revenue by Application (2018-2029) 42
7.4 Europe Radioimmunotherapy Revenue by Country (2018-2029) 43
7.4.1 Germany 45
7.4.2 France 45
7.4.3 U.K. 46
7.4.4 Italy 46
7.4.5 Russia 47
8 Asia Pacific 48
8.1 Asia Pacific Radioimmunotherapy Revenue by Company (2021-2023) 48
8.2 Asia Pacific Radioimmunotherapy Revenue by Type (2018-2029) 49
8.3 Asia Pacific Radioimmunotherapy Revenue by Application (2018-2029) 50
8.4 Asia Pacific Radioimmunotherapy Revenue by Region (2018-2029) 51
8.4.1 China 53
8.4.2 Japan 53
8.4.3 South Korea 54
8.4.4 India 54
8.4.5 Southeast Asia 55
9 Latin America 56
9.1 Latin America Radioimmunotherapy Revenue by Company (2021-2023) 56
9.2 Latin America Radioimmunotherapy Revenue by Type (2018-2029) 57
9.3 Latin America Radioimmunotherapy Revenue by Application (2018-2029) 58
9.4 Latin America Radioimmunotherapy Revenue by Country (2018-2029) 58
9.4.1 Mexico 60
9.4.2 Brazil 60
10 Middle East and Africa 61
10.1 Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2023) 61
10.2 Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2029) 62
10.3 Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2029) 63
10.4 Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2029) 63
10.4.1 Middle East 65
10.4.2 Africa 65
11 Company Profiles 66
11.1 Bayer 66
11.1.1 Bayer Company Details 66
11.1.2 Bayer Business Overview 66
11.1.3 Bayer Radioimmunotherapy Products and Services 67
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2023) 68
11.1.5 Bayer Radioimmunotherapy SWOT Analysis 68
11.1.6 Bayer Business Strategy 69
11.2 Novartis 69
11.2.1 Novartis Company Details 70
11.2.2 Novartis Business Overview 70
11.2.3 Novartis Radioimmunotherapy Products and Services 71
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2023) 72
11.2.5 Novartis Radioimmunotherapy SWOT Analysis 72
11.2.6 Novartis Business Strategy 73
11.3 Lantheus 73
11.3.1 Lantheus Company Details 74
11.3.2 Lantheus Business Overview 74
11.3.3 Lantheus Radioimmunotherapy Products and Services 75
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2023) 75
11.3.5 Lantheus Radioimmunotherapy SWOT Analysis 76
11.3.6 Lantheus Business Strategy 77
11.4 Aurobindo Pharma 77
11.4.1 Aurobindo Pharma Company Details 78
11.4.2 Aurobindo Pharma Business Overview 78
11.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 79
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2023) 79
11.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80
11.4.6 Aurobindo Pharma Business Strategy 81
11.5 Mundipharma 81
11.5.1 Mundipharma Company Details 81
11.5.2 Mundipharma Business Overview 82
11.5.3 Mundipharma Radioimmunotherapy Products and Services 83
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2023) 83
11.5.5 Mundipharma Business Strategy 84
11.6 China Isotope & Radiation 84
11.6.1 China Isotope & Radiation Company Details 84
11.6.2 China Isotope & Radiation Business Overview 85
11.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 85
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2023) 86
11.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86
11.6.6 China Isotope & Radiation Business Strategy 87
11.7 Curium Pharmaceuticals 88
11.7.1 Curium Pharmaceuticals Company Details 88
11.7.2 Curium Pharmaceuticals Business Overview 88
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 89
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2023) 89
11.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90
11.7.6 Curium Pharmaceuticals Business Strategy 91
11.8 Gilead Sciences 91
11.8.1 Gilead Sciences Company Details 92
11.8.2 Gilead Sciences Business Overview 92
11.8.3 Gilead Sciences Radioimmunotherapy Products and Services 93
11.8.4 Gilead Sciences Business Strategy 93
11.9 Clarity Pharmaceuticals 94
11.9.1 Clarity Pharmaceuticals Company Details 94
11.9.2 Clarity Pharmaceuticals Business Overview 94
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95
11.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95
11.9.5 Clarity Pharmaceuticals Business Strategy 96
11.10 Curasight 96
11.10.1 Curasight Company Details 96
11.10.2 Curasight Business Overview 97
11.10.3 Curasight Radioimmunotherapy Products and Services 97
11.10.4 Curasight Radioimmunotherapy SWOT Analysis 98
11.10.5 Curasight Business Strategy 98
11.11 Nordic Nanovector 99
11.11.1 Nordic Nanovector Company Details 99
11.11.2 Nordic Nanovector Business Overview 100
11.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 100
11.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 100
11.11.5 Nordic Nanovector Business Strategy 101
11.12 Philogen 102
11.12.1 Philogen Company Details 102
11.12.2 Philogen Business Overview 102
11.12.3 Philogen Radioimmunotherapy Products and Services 103
11.12.4 Philogen Radioimmunotherapy SWOT Analysis 103
11.12.5 Philogen Business Strategy 104
11.13 RadioMedix 104
11.13.1 RadioMedix Company Details 104
11.13.2 RadioMedix Business Overview 105
11.13.3 RadioMedix Radioimmunotherapy Products and Services 105
11.13.4 RadioMedix Business Strategy 105
11.14 Telix Pharmaceuticals 106
11.14.1 Telix Pharmaceuticals Company Details 106
11.14.2 Telix Pharmaceuticals Business Overview 107
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 107
11.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108
11.14.5 Telix Pharmaceuticals Business Strategy 108
11.15 Orano Med 109
11.15.1 Orano Med Company Details 109
11.15.2 Orano Med Business Overview 110
11.15.3 Orano Med Radioimmunotherapy Products and Services 110
11.15.4 Orano Med Radioimmunotherapy SWOT Analysis 110
11.15.5 Orano Med Business Strategy 111
11.16 Actinium Pharmaceuticals 111
11.16.1 Actinium Pharmaceuticals Company Details 111
11.16.2 Actinium Pharmaceuticals Business Overview 112
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112
11.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113
11.16.5 Actinium Pharmaceuticals Business Strategy 113
11.17 Y-mAbs Therapeutics 114
11.17.1 Y-mAbs Therapeutics Company Details 114
11.17.2 Y-mAbs Therapeutics Business Overview 114
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115
11.17.4 Y-mAbs Therapeutics Business Strategy 116
11.18 Fusion Pharmaceuticals 116
11.18.1 Fusion Pharmaceuticals Company Details 116
11.18.2 Fusion Pharmaceuticals Business Overview 117
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117
11.18.4 Fusion Pharmaceuticals Business Strategy 118
12 Radioimmunotherapy Market Dynamics 120
12.1 Radioimmunotherapy Industry Trends 120
12.2 Radioimmunotherapy Market Drivers 121
12.3 Radioimmunotherapy Market Challenges 122
12.4 Radioimmunotherapy Market Restraints 123
13 Research Findings and Conclusion 124
14 Appendix 126
14.1 Research Methodology 126
14.1.1 Methodology/Research Approach 126
14.1.2 Data Source 129
14.2 Author Details 132
14.3 Disclaimer 135



 

ページTOPに戻る


 

Summary

Due to the COVID-19 pandemic, the global Radioimmunotherapy market size was US$ 1042.83 million in 2022 and is forecast to a readjusted size of US$ 4479 million by 2029 with a CAGR of 17.43% during the forecast period 2023-2029.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, and etc. In 2022, the global top five players hold a share approximately 99.25% in terms of revenue.
The United States Radioimmunotherapy market size was US$ 504.62 million in 2022, while China size was US$ 23.72 million. The proportion of the United States was 48.39% in 2022, while China percentage was 2.27%, and it is predicted that China share will reach 1.44% in 2029, trailing a CAGR of 20.26 % through the analysis period. As for the Europe Radioimmunotherapy landscape, Germany is projected to reach US$ 327 million by 2029.

The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Radioimmunotherapy market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Radioimmunotherapy market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Radioimmunotherapy market. Readers of the report can become informed about current and future trends of the global Radioimmunotherapy market and how they will impact market growth during the forecast period.

By Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
On Pipeline
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Segment by Type
Beta-emitting
Targeted Alpha Therapy

Segment by Application
Non Hodgkin Lymphoma (NHL)
Solid Tumor

By Region
North America
United States
Canada

Asia-Pacific
China
Japan
South Korea
India
Southeast Asia

Europe
Germany
France
U.K.
Italy
Russia

Latin America
Mexico
Brazil

Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Radioimmunotherapy in global and regional level.
Chapter 3: Detailed analysis of Radioimmunotherapy companies鈥 competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 10: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin, and Business Strategy, etc.
Chapter 12: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13: Research Findings and Conclusion



ページTOPに戻る


Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1
1.2.2 Targeted Alpha Therapy 3
1.2.3 Beta-emitting 4
1.3 Market by Application 7
1.3.1 Global Radioimmunotherapy Market Growth by Application: 2018 VS 2022 VS 2029 7
1.3.2 Non Hodgkin Lymphoma (NHL) 9
1.3.3 Solid Tumor 10
1.4 Assumptions and Limitations 12
1.5 Study Objectives 13
1.6 Years Considered 14
2 Market Perspective 15
2.1 Global Radioimmunotherapy Market Size 2018-2029 15
2.2 Radioimmunotherapy Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2029 16
2.3 Global Radioimmunotherapy Market Size by Region (2018-2023) 18
2.4 Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) 20
2.5 Global Top 10 Radioimmunotherapy Countries Ranking by Market Size 21
3 Radioimmunotherapy Competition by Company 23
3.1 Global Radioimmunotherapy Revenue by Players 23
3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2023) 23
3.1.2 Global Radioimmunotherapy Market Share by Players (2018-2023) 24
3.2 Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) 25
3.3 Company Covered: Ranking by Radioimmunotherapy Revenue 25
3.4 Global Radioimmunotherapy Market Concentration Ratio 26
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI) 26
3.4.2 Global Top 5 Companies by Radioimmunotherapy Revenue in 2022 27
3.5 Global Key Players of Radioimmunotherapy Head office and Area Served 27
3.6 Global Key Players of Radioimmunotherapy, Product and Application 28
3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry 28
3.8 Mergers & Acquisitions, Expansion Plans 29
4 Global Radioimmunotherapy Breakdown Data by Type 30
4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2023) 30
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) 31
5 Global Radioimmunotherapy Breakdown Data by Application 32
5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2023) 32
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) 33
6 North America 34
6.1 North America Radioimmunotherapy Revenue by Company (2021-2023) 34
6.2 North America Radioimmunotherapy Revenue by Type (2018-2029) 35
6.3 North America Radioimmunotherapy Revenue by Application (2018-2029) 36
6.4 North America Radioimmunotherapy Revenue by Country (2018-2029) 37
6.4.1 United States 38
6.4.2 Canada 39
7 Europe 40
7.1 Europe Radioimmunotherapy Revenue by Company (2021-2023) 40
7.2 Europe Radioimmunotherapy Revenue by Type (2018-2029) 41
7.3 Europe Radioimmunotherapy Revenue by Application (2018-2029) 42
7.4 Europe Radioimmunotherapy Revenue by Country (2018-2029) 43
7.4.1 Germany 45
7.4.2 France 45
7.4.3 U.K. 46
7.4.4 Italy 46
7.4.5 Russia 47
8 Asia Pacific 48
8.1 Asia Pacific Radioimmunotherapy Revenue by Company (2021-2023) 48
8.2 Asia Pacific Radioimmunotherapy Revenue by Type (2018-2029) 49
8.3 Asia Pacific Radioimmunotherapy Revenue by Application (2018-2029) 50
8.4 Asia Pacific Radioimmunotherapy Revenue by Region (2018-2029) 51
8.4.1 China 53
8.4.2 Japan 53
8.4.3 South Korea 54
8.4.4 India 54
8.4.5 Southeast Asia 55
9 Latin America 56
9.1 Latin America Radioimmunotherapy Revenue by Company (2021-2023) 56
9.2 Latin America Radioimmunotherapy Revenue by Type (2018-2029) 57
9.3 Latin America Radioimmunotherapy Revenue by Application (2018-2029) 58
9.4 Latin America Radioimmunotherapy Revenue by Country (2018-2029) 58
9.4.1 Mexico 60
9.4.2 Brazil 60
10 Middle East and Africa 61
10.1 Middle East and Africa Radioimmunotherapy Revenue by Company (2021-2023) 61
10.2 Middle East and Africa Radioimmunotherapy Revenue by Type (2018-2029) 62
10.3 Middle East and Africa Radioimmunotherapy Revenue by Application (2018-2029) 63
10.4 Middle East and Africa Radioimmunotherapy Revenue by Country (2018-2029) 63
10.4.1 Middle East 65
10.4.2 Africa 65
11 Company Profiles 66
11.1 Bayer 66
11.1.1 Bayer Company Details 66
11.1.2 Bayer Business Overview 66
11.1.3 Bayer Radioimmunotherapy Products and Services 67
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2023) 68
11.1.5 Bayer Radioimmunotherapy SWOT Analysis 68
11.1.6 Bayer Business Strategy 69
11.2 Novartis 69
11.2.1 Novartis Company Details 70
11.2.2 Novartis Business Overview 70
11.2.3 Novartis Radioimmunotherapy Products and Services 71
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2023) 72
11.2.5 Novartis Radioimmunotherapy SWOT Analysis 72
11.2.6 Novartis Business Strategy 73
11.3 Lantheus 73
11.3.1 Lantheus Company Details 74
11.3.2 Lantheus Business Overview 74
11.3.3 Lantheus Radioimmunotherapy Products and Services 75
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2023) 75
11.3.5 Lantheus Radioimmunotherapy SWOT Analysis 76
11.3.6 Lantheus Business Strategy 77
11.4 Aurobindo Pharma 77
11.4.1 Aurobindo Pharma Company Details 78
11.4.2 Aurobindo Pharma Business Overview 78
11.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services 79
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2023) 79
11.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis 80
11.4.6 Aurobindo Pharma Business Strategy 81
11.5 Mundipharma 81
11.5.1 Mundipharma Company Details 81
11.5.2 Mundipharma Business Overview 82
11.5.3 Mundipharma Radioimmunotherapy Products and Services 83
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2023) 83
11.5.5 Mundipharma Business Strategy 84
11.6 China Isotope & Radiation 84
11.6.1 China Isotope & Radiation Company Details 84
11.6.2 China Isotope & Radiation Business Overview 85
11.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services 85
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2023) 86
11.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis 86
11.6.6 China Isotope & Radiation Business Strategy 87
11.7 Curium Pharmaceuticals 88
11.7.1 Curium Pharmaceuticals Company Details 88
11.7.2 Curium Pharmaceuticals Business Overview 88
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services 89
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2023) 89
11.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis 90
11.7.6 Curium Pharmaceuticals Business Strategy 91
11.8 Gilead Sciences 91
11.8.1 Gilead Sciences Company Details 92
11.8.2 Gilead Sciences Business Overview 92
11.8.3 Gilead Sciences Radioimmunotherapy Products and Services 93
11.8.4 Gilead Sciences Business Strategy 93
11.9 Clarity Pharmaceuticals 94
11.9.1 Clarity Pharmaceuticals Company Details 94
11.9.2 Clarity Pharmaceuticals Business Overview 94
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services 95
11.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis 95
11.9.5 Clarity Pharmaceuticals Business Strategy 96
11.10 Curasight 96
11.10.1 Curasight Company Details 96
11.10.2 Curasight Business Overview 97
11.10.3 Curasight Radioimmunotherapy Products and Services 97
11.10.4 Curasight Radioimmunotherapy SWOT Analysis 98
11.10.5 Curasight Business Strategy 98
11.11 Nordic Nanovector 99
11.11.1 Nordic Nanovector Company Details 99
11.11.2 Nordic Nanovector Business Overview 100
11.11.3 Nordic Nanovector Radioimmunotherapy Products and Services 100
11.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis 100
11.11.5 Nordic Nanovector Business Strategy 101
11.12 Philogen 102
11.12.1 Philogen Company Details 102
11.12.2 Philogen Business Overview 102
11.12.3 Philogen Radioimmunotherapy Products and Services 103
11.12.4 Philogen Radioimmunotherapy SWOT Analysis 103
11.12.5 Philogen Business Strategy 104
11.13 RadioMedix 104
11.13.1 RadioMedix Company Details 104
11.13.2 RadioMedix Business Overview 105
11.13.3 RadioMedix Radioimmunotherapy Products and Services 105
11.13.4 RadioMedix Business Strategy 105
11.14 Telix Pharmaceuticals 106
11.14.1 Telix Pharmaceuticals Company Details 106
11.14.2 Telix Pharmaceuticals Business Overview 107
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services 107
11.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis 108
11.14.5 Telix Pharmaceuticals Business Strategy 108
11.15 Orano Med 109
11.15.1 Orano Med Company Details 109
11.15.2 Orano Med Business Overview 110
11.15.3 Orano Med Radioimmunotherapy Products and Services 110
11.15.4 Orano Med Radioimmunotherapy SWOT Analysis 110
11.15.5 Orano Med Business Strategy 111
11.16 Actinium Pharmaceuticals 111
11.16.1 Actinium Pharmaceuticals Company Details 111
11.16.2 Actinium Pharmaceuticals Business Overview 112
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services 112
11.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis 113
11.16.5 Actinium Pharmaceuticals Business Strategy 113
11.17 Y-mAbs Therapeutics 114
11.17.1 Y-mAbs Therapeutics Company Details 114
11.17.2 Y-mAbs Therapeutics Business Overview 114
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services 115
11.17.4 Y-mAbs Therapeutics Business Strategy 116
11.18 Fusion Pharmaceuticals 116
11.18.1 Fusion Pharmaceuticals Company Details 116
11.18.2 Fusion Pharmaceuticals Business Overview 117
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services 117
11.18.4 Fusion Pharmaceuticals Business Strategy 118
12 Radioimmunotherapy Market Dynamics 120
12.1 Radioimmunotherapy Industry Trends 120
12.2 Radioimmunotherapy Market Drivers 121
12.3 Radioimmunotherapy Market Challenges 122
12.4 Radioimmunotherapy Market Restraints 123
13 Research Findings and Conclusion 124
14 Appendix 126
14.1 Research Methodology 126
14.1.1 Methodology/Research Approach 126
14.1.2 Data Source 129
14.2 Author Details 132
14.3 Disclaimer 135



 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る